네라멕산

Neramexane
네라멕산
Neramexane.svg
임상 데이터
ATC 코드
  • 없음.
식별자
  • 1,3,5,5-펜타메틸시클로헥사나민
CAS 번호
PubChem CID
켐스파이더
유니
CompTox 대시보드 (EPA )
ECHA 정보 카드100.107.752 Edit this at Wikidata
화학 및 물리 데이터
공식C11H23N
몰 질량169.312 g/120−1
3D 모델(JSmol)
  • CC1(CC(C1)(C)N)(C)C
  • InChI=1S/C11H23N/c1-9(2)6-10(3,4)8-11(5,12)7-9/h6-8,12H2,1-5H3 ☒N
  • 키: OGZQTTHDGQBL-UHFFFAOYSA-N ☒N
☒NcheckY (이게 뭐죠?) (표준)

Neramexane은 NMDA 길항제[2] 역할을 하며 신경 보호 [3]효과가 있는 memantine과 [1]관련된 약물입니다.이명은 이명,[4][5] 알츠하이머병,[6] 약물중독[7], 진통제 [8]등 다양한 용도로 개발되고 있다.동물 연구는 또한 항우울제와[9] 누트로픽[10] 작용을 제안하여 이 약이 사용될 수 있는 다양한 잠재적 응용 분야가 있다.또한 니코틴성 아세틸콜린 수용체 [11]길항제 역할을 한다.

임상시험 결과 50mg 이상의 복용량이 16주 [12]동안 이명을 안전하게 개선한 것으로 나타났다.

「 」를 참조해 주세요.

레퍼런스

  1. ^ Gilling K, Jatzke C, Wollenburg C, Vanejevs M, Kauss V, Jirgensons A, Parsons CG (2007). "A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization". Journal of Neural Transmission. 114 (12): 1529–37. doi:10.1007/s00702-007-0792-7. PMID 17728997. S2CID 8654883.
  2. ^ Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J (2002). "Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists". Current Pharmaceutical Design. 8 (10): 835–43. doi:10.2174/1381612024607117. PMID 11945134.
  3. ^ Danysz W, Parsons CG (March 2002). "Neuroprotective potential of ionotropic glutamate receptor antagonists". Neurotoxicity Research. 4 (2): 119–26. doi:10.1080/10298420290015872. PMID 12829411. S2CID 9413469.
  4. ^ "Neramexane for 이명" 임상시험번호 NCT00405886 ClinicalTrials.gov
  5. ^ 임상시험번호 NCT00739635 "주관적 이명이 있는 환자의 Neramexane의 효율성, 안전성 및 허용가능성" (ClinicalTrials.gov )
  6. ^ Rammes G, Schierloh A (February 2006). "Neramexane (merz pharmaceuticals/forest laboratories)". IDrugs. 9 (2): 128–35. PMID 16523403.
  7. ^ Kotlinska J, Biala G, Rafalski P, Bochenski M, Danysz W (October 2004). "Effect of neramexane on ethanol dependence and reinforcement". European Journal of Pharmacology. 503 (1–3): 95–8. doi:10.1016/j.ejphar.2004.09.036. PMID 15496302.
  8. ^ Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD (January 2008). "Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia". European Journal of Pain. 12 (1): 17–29. doi:10.1016/j.ejpain.2007.02.002. PMID 17449306. S2CID 2875679.
  9. ^ Kos T, Legutko B, Danysz W, Samoriski G, Popik P (September 2006). "Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice". The Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1128–36. doi:10.1124/jpet.106.103697. PMID 16740621. S2CID 11450694.
  10. ^ Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM (October 2006). "Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane". Pharmacology, Biochemistry, and Behavior. 85 (2): 298–306. doi:10.1016/j.pbb.2006.08.011. PMID 17045636. S2CID 9614195.
  11. ^ Plazas PV, Savino J, Kracun S, Gomez-Casati ME, Katz E, Parsons CG, et al. (July 2007). "Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors". European Journal of Pharmacology. 566 (1–3): 11–9. doi:10.1016/j.ejphar.2007.03.026. PMID 17466293.
  12. ^ Suckfüll M, Althaus M, Ellers-Lenz B, Gebauer A, Görtelmeyer R, Jastreboff PJ, et al. (January 2011). "A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus". BMC Ear, Nose and Throat Disorders. 11: 1. doi:10.1186/1472-6815-11-1. PMC 3031239. PMID 21223542.


Stub icon

신경계에 관한 이 약물 기사는 엉터리이다.위키피디아를 확장함으로써 위키피디아를 도울 수 있습니다.